Peter Nigrovic, MD, provides a practical guide to the diagnosis & treatment of macrophage activation syndrome (MAS) in children & adults.
Lung Cancer in RA & RA-ILD
Brooks et al. evaluated the risk of lung cancer in patients with rheumatoid arthritis (RA) and RA-associated interstitial lung disease (ILD) compared with the risk in matched controls without RA or RA-ILD. Understanding whether RA predisposes someone to lung cancer and whether patients with RA-ILD represent a uniquely high-risk group could inform cancer-screening strategies.
Young Adults with Psoriatic Disease at Risk of Early Cardiovascular Disease
Background/Purpose Psoriasis and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated with traditional cardiovascular disease risk factors and subclinical atherosclerosis. In older adults, systemic inflammation from psoriasis and PsA accelerates atherosclerosis, and these conditions are independent risk factors for severe cardiovascular disease…
Autoantibodies Illuminate Lupus Nephritis
Fava et al. investigated longitudinal autoantibody profiles in patients with lupus nephritis (LN) to define serological biomarkers of histologic class. They found that baseline levels of anti-C1q and anti-double-stranded DNA antibodies may serve as noninvasive biomarkers of proliferative LN and anti-C1q antibodies may predict complete response.
Anti-Infliximab Antibodies Predict Response in Axial Spondyloarthritis
Pimentel et al. evaluated the influence of anti-infliximab antibodies on patients with axial spondyloarthritis. The researchers found that anti-infliximab antibodies were associated with decreased infliximab performance and difficulty tapering its dosage, as well as a good clinical response to a second, alternate tumor necrosis factor inhibitor.
Glucocorticoids Increase Infections, Mortality
Figueroa-Parra et al. set out to evaluate the effect of glucocorticoid regimens on renal response, infections and mortality rates among patients with lupus nephritis (LN). The researchers analyzed the control arms of randomized clinical trials and found a higher exposure to glucocorticoids during the initial treatment of LN was associated with better renal outcomes, at the cost of increased infections and mortality.
Tofacitinib Increases Risk of Venous Thromboembolism
Background & Objectives The ORAL Surveillance trial (NCT02092467), a postauthorization safety study of tofacitinib in patients with rheumatoid arthritis (RA) aged 50 years or older with at least one additional cardiovascular risk factor, found a dose-dependent increase in venous thromboembolism (VTE) and pulmonary embolism (PE) events when patients were treated with tofacitinib vs. a tumor…
Changes in the Rheumatology Workforce
Mannion et al. set out to describe the adult rheumatology workforce in the U.S. by measuring the number of rheumatologists and advanced practice providers entering and exiting the field and studying their demographics.
Calprotectin Shows Promise as APS Thrombocytopenia Biomarker
Hoy et al. sought to evaluate the presence, clinical associations, and potential mechanistic roles of circulating calprotectin in a cohort of patients with primary antiphospholipid syndrome (APS) and those with antiphospholipid antibodies. Calprotectin levels were higher in patients with primary APS and those with antiphospholipid antibodies than in healthy controls. These data suggest that calprotectin has the potential to be a functional biomarker and a new therapeutic target for APS-related thrombocytopenia.
Can an App Reduce the Need for In-Person Visits?
Solomon et al. examined whether a mobile application (app) for patients with rheumatoid arthritis integrated in the electronic health record would be used by patients and rheumatologists.
- 1
- 2
- 3
- …
- 14
- Next Page »